## BLV hurts your profits

The hidden costs of BLV extend beyond obvious cases of lymphosarcoma[3]

- Reduced reproductive efficiency
- Premature culling
- Decreased milk production
- Slaughter condemnation
- Difficulties with export
- Death

Up to

**$412**

for one clinical case[3]

Annual cost

**$6,400**

for an average infected herd[3]

Herd Management Diagnostics

**VMRD**
Veterinary Medical Research & Development
PO Box 502, Pullman, WA 99163
509-334-5815 | Fax 509-332-5356

Ask Questions
vmrd@vmrd.com

vmrd.com

Copyright © 2016, VMRD. All Rights Reserved. Printed in the USA.

# ENZOOTIC BOVINE LEUKOSIS (BLV)

## Protect Your Herd. Protect Your Profits.

Herd Management Diagnostics

## Why you need to protect your herd from BLV

- Infection is lifelong with no effective treatment or vaccine
- Primarily transmitted through blood, including transfer during routine procedures
- Can affect the immune system leading to impaired response to diseases and vaccines[1]
- More than 21 countries have eradicated BLV, potentially affecting US product exports[2]

## What you can do to protect your profits

### Diagnostic Testing for BLV Control

1. Determine prevalence to target management
2. Screen herd regularly to monitor effectiveness

| | Herds Affected | Prevalence within herd |
|---|---|---|
| Dairy[3] | 89% | 39–68% |
| Beef[2] | 39% | 1–10% |

**HIGH PREVALENCE HERDS**

### Test and Manage

- Reduce transmission by protecting calves and practicing good hygiene

**LOW PREVALENCE HERDS**

### Test and Eradicate

- Identify positives and cull
- Introduce only negative animals

### Test and Segregate

- Manage positive and negative herds separately with strict quarantine
- Protect calves and test all born to positive dams



### Protect Calves

- Heat treat colostrum and milk
- Feed colostrum from positive dams to their own calves

### Maintain Good Hygiene

- Single-use needles for injections
- Disinfect blood-contaminated equipment
- Use effective insect control


References
1. Frie MC and Coussens PM. 2015. Vet immunol Immunopath 163:103-114
2. Bartlett PC et al. 2014. JAVMA 244(8): 914-922
3. Rhodes JK et al. 2003. JAVMA 223(3): 346-352